CEP-701

DRUG3 trials

Sponsors

Cephalon, M.D. Anderson Cancer Center

Conditions

Acute Myeloid LeukemiaLeukemiaMyelofibrosisProstate Cancer

Phase 2

Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)

CompletedNCT00079482

CephalonAcute Myeloid Leukemia

Start: 2003-10-31End: 2010-01-31Updated: 2016-07-21

Study of CEP-701 in Treatment of Prostate Cancer

CompletedNCT00081601

CephalonProstate Cancer

Start: 2004-03-31End: 2005-06-30Target: 30Updated: 2012-08-24

CEP-701 for PH-negative Myelofibrosis

CompletedNCT00494585

M.D. Anderson Cancer CenterLeukemia, Myelofibrosis

Start: 2007-06-30End: 2010-05-31Updated: 2012-06-25

Related Papers

Monitoramento do Horizonte Tecnológico (MHT) de Inibidores de Janus Quinase (JAKi) para o Tratamento de Mielofibrose

Epidemiologia e Serviços de Saúde2025-01-01

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse.

2011-01-26311 citations

Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.

2009-12-11166 citations